J
Jonathan A. Fletcher
Researcher at Brigham and Women's Hospital
Publications - 426
Citations - 57627
Jonathan A. Fletcher is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: GiST & PDGFRA. The author has an hindex of 109, co-authored 413 publications receiving 53642 citations. Previous affiliations of Jonathan A. Fletcher include Albany Medical College & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Diagnostic Relevance of Clonal Cytogenetic Aberrations in Malignant Soft-Tissue Tumors
Jonathan A. Fletcher,Harry P.W. Kozakewich,Fredric A. Hoffer,Janice M. Lage,Noel Weidner,Robert I. Tepper,Geraldine S. Pinkus,Cynthia C. Morton,Joseph M. Corson +8 more
TL;DR: Cytogenetic analyses reveal clonal chromosome aberrations in virtually all malignant soft-tissue tumors, particularly in small round-cell tumors in children.
Journal ArticleDOI
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours
Ping Chi,Yu Chen,Lei Zhang,Xingyi Guo,John Wongvipat,Tambudzai Shamu,Jonathan A. Fletcher,Scott Dewell,Robert G. Maki,Deyou Zheng,Cristina R. Antonescu,C. David Allis,Charles L. Sawyers,Charles L. Sawyers +13 more
TL;DR: It is proposed that GIST arises from ICCs with high levels of endogenous ETV1 expression that, when coupled with an activating KIT mutation, drives an oncogenic ETS transcriptional program.
Journal ArticleDOI
USP6 (Tre2) Fusion Oncogenes in Aneurysmal Bone Cyst
Andre M. Oliveira,Andre M. Oliveira,Bae Li Hsi,Stanislawa Weremowicz,Andrew E. Rosenberg,Paola Dal Cin,Nora E. Joseph,Julia A. Bridge,Antonio R. Perez-Atayde,Jonathan A. Fletcher +9 more
TL;DR: It is shown that a recurring ABC chromosomal translocation t(16;17)(q22;p13) creates a fusion gene in which the osteoblast cadherin 11 gene (CDH11) promoter region on 16q22 is juxtaposed to the entire ubiquitin-specific protease USP6 (Tre2) coding sequence on 17p13.
Journal ArticleDOI
Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
TL;DR: Findings suggest that 17-AAG biological effects in KIT-positive GISTs result mainly from KIT oncoprotein inhibition, and suggests that HSP90 inhibition provides a therapeutic solution to the challenge of heterogeneous imatinib resistance mutations in GIST patients.
Journal ArticleDOI
The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor.
Cheng-Han Lee,Adrián Mariño-Enríquez,Wen-Bin Ou,Meijun Zhu,Rola H. Ali,Sarah Chiang,Frédéric Amant,C. Blake Gilks,Matt van de Rijn,Esther Oliva,Maria Debiec-Rychter,Paola Dal Cin,Jonathan A. Fletcher,Marisa R. Nucci +13 more
TL;DR: Tumors with YWHAE-FAM22 rearrangements constitute a distinct group of ESS, which is associated with high-grade morphology and aggressive clinical behavior compared to JAZF1 ESS.